ACRS Stock Analysis: Aclaris Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 758m USD | 12M Return: 176.8% | US00461U1051 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 13.7M
Qual. Beats: 0
Rev. Trend: -88.9%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Aclaris Therapeutics (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company headquartered in Wayne, Pennsylvania, focused on discovering and developing novel small-molecule and biologic product candidates for immuno-inflammatory diseases. The company was incorporated in 2012 and went public in 2015. As a clinical-stage issuer with no commercial products, Aclaris is pre-revenue and funds its operations through equity financing and capital markets rather than product sales, which is typical for the biopharmaceutical sub-industry.
Its pipeline is centered on modulating immune pathways implicated in atopic, respiratory, and autoimmune conditions. Lead candidate Bosakitug (ATI-045) is an anti-TSLP monoclonal antibody in Phase 2 development across atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and COPD. ATI-2138, a dual ITK/JAK3 inhibitor, is in Phase 2a for T cell-mediated autoimmune diseases, while ATI-052, an anti-TSLP/anti-IL4R bispecific antibody, is in Phase 1b. Earlier-stage assets include ATI-9494 (an oral covalent ITK/TXK inhibitor) and Lepzacitinib (a soft JAK1/3 inhibitor) for dermatologic conditions.
- Bosakitug Phase 2 atopic dermatitis data readout nears
- Cash burn fuels potential dilutive financing risk
- Dupixent competition pressures atopic dermatitis market entry
| Net Income: -75.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.35 > 0.02 and ΔFCF/TA -9.91 > 1.0 |
| NWC/Revenue: 845.9% < 20% (prev 460.8%; Δ 385.1% < -1%) |
| CFO/TA -0.35 > 3% & CFO -62.1m > Net Income -75.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (142.7m) vs 12m ago 16.44% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 4.46% > 50% (prev 8.88%; Δ -4.42% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.39 (Total Current Assets 97.8m - Total Current Liabilities 28.2m) / Total Assets 179.7m |
| B: -5.62 (Retained Earnings -1.01b / Total Assets 179.7m) |
| C: -0.41 (EBIT TTM -75.7m / Avg Total Assets 184.4m) |
| D: 2.26 (Book Value of Equity 124.6m / Total Liabilities 55.1m) |
| Altman-Z'' = -16.16 = D |
| DSRI: 3.0 (Receivables 6.21m/194k, Revenue 8.22m/16.8m) |
| GMI: 0.17 (GM 16.22% / 95.61%) |
| AQI: 1.02 (AQ_t 0.45 / AQ_t-1 0.44) |
| SGI: 0.49 (Revenue 8.22m / 16.8m) |
| TATA: -0.08 (NI -75.7m - CFO -62.1m) / TA 179.7m) |
| Beneish M = -2.50 (Cap -4..+1) = BBB |
As of October 01, 2026, the stock is trading at USD 5.26 with a total of 2,263,471 shares traded. Over the past week, the price has changed by +0.00%, over one month by -13.06%, over three months by -0.57% and over the past year by +176.84%.
Current recommended Stop Loss: 4.70 (which is 10.6% or 1.6 ATR below the current price).
Aclaris Therapeutics has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ACRS.
- StrongBuy: 3
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 10.2 | 93.5% |
P/S = 92.2344
P/B = 6.2091
P/EG = -0.13
Revenue TTM = 8.22m USD
EBIT TTM = -75.7m USD
EBITDA TTM = -75.1m USD
Long Term Debt = unknown (none)
Short Term Debt = 551k USD (from shortTermDebt, last fiscal year)
Debt = 2.54m USD (from shortLongTermDebtTotal, last fiscal year) + Leases 426k
Net Debt = -89.0m USD (calculated: Debt 2.54m - CCE 91.6m)
Enterprise Value = 669.1m USD (758.1m + Debt 2.54m - CCE 91.6m)
Interest Coverage Ratio = unknown (Ebit TTM -75.7m / Interest Expense TTM 0.0)
EV/FCF = -10.76x (Enterprise Value 669.1m / FCF TTM -62.2m)
FCF Yield = -9.29% (FCF TTM -62.2m / Enterprise Value 669.1m)
FCF Margin = -756.5% (FCF TTM -62.2m / Revenue TTM 8.22m)
Net Margin = -921.5% (Net Income TTM -75.7m / Revenue TTM 8.22m)
Gross Margin = unknown ((Revenue TTM 8.22m - Cost of Revenue TTM 361k) / Revenue TTM)
Tobins Q-Ratio = 3.72 (Enterprise Value 669.1m / Total Assets 179.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 2.54m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -59.8m (EBIT -75.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.46 (Total Current Assets 97.8m / Total Current Liabilities 28.2m)
Debt / Equity = 0.02 (Debt 2.54m / totalStockholderEquity, last quarter 124.6m)
Debt / EBITDA = 1.19 (negative EBITDA) (Net Debt -89.0m / EBITDA -75.1m)
Debt / FCF = 1.43 (negative FCF - burning cash) (Net Debt -89.0m / FCF TTM -62.2m)
Total Stockholder Equity = 122.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -41.07% (Net Income -75.7m / Total Assets 179.7m)
RoE = -61.65% (Net Income TTM -75.7m / Total Stockholder Equity 122.9m)
RoCE = -50.01% (EBIT -75.7m / Capital Employed (Total Assets 179.7m - Current Liab 28.2m))
RoIC = -39.47% (negative operating profit) (NOPAT -59.8m / Invested Capital 151.6m)
WACC = 11.36% (E(758.1m)/V(760.6m) * Re(11.40%) + D(2.54m)/V(760.6m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.40% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.27 | Cagr: 36.33%
[DCF] Fair Price = unknown (Cash Flow -62.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.04 | # QB: 0
Revenue Correlation: -88.90 | Revenue CAGR: -40.48% | SUE: 0.05 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.17 | Chg30d=+4.35% | Revisions=+38% | Analysts=10
EPS current Year (2026-12-31): EPS=-0.64 | Chg30d=+1.68% | Revisions=+10% | GrowthEPS=-21.5% | GrowthRev=-19.0%
EPS next Year (2027-12-31): EPS=-0.79 | Chg30d=+5.02% | Revisions=+0% | GrowthEPS=-22.2% | GrowthRev=-15.8%
[Analyst] Revisions Ratio: +17% (up=12, down=8)